MARKET

BIIB

BIIB

Biogen Inc
NASDAQ
232.85
-1.79
-0.76%
After Hours: 232.00 -0.85 -0.37% 19:41 12/04 EST
OPEN
234.11
PREV CLOSE
234.64
HIGH
236.24
LOW
232.32
VOLUME
945.66K
TURNOVER
0
52 WEEK HIGH
319.76
52 WEEK LOW
220.86
MARKET CAP
33.74B
P/E (TTM)
23.16
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at BIIB last week (1127-1201)?
Weekly Report · 1d ago
Biotechs post record gains in November amid improving outlook
Healthcare biotechs post record gains in november amid improving outlook. Gene therapy developers outperformed and pharma giants look for m&a opportunities in the industry. November was the best month for biotechs since november 2020. The spdr s&p biotech etf climbed 14% in november while the healthcare sector rose only 9%.
Seeking Alpha · 2d ago
Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why
NASDAQ · 4d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cybin (CYBN), Nevro Corp (NVRO) and Biogen (BIIB)
TipRanks · 4d ago
Noteworthy Thursday Option Activity: BIIB, ADM, TMUS
NASDAQ · 4d ago
RBC starts Lexeo at outperform, cites Friedreich's ataxia drug opportunity
Healthcare rbc starts lexeo at outperform, cites friedreich's ataxia drug opportunity. Rbc capital markets has initiated coverage of newly publiclexeo therapeutics with an outperform rating. The investment firm cites the company's commercial opportunity for its friedreich's atxia drug candidate.
Seeking Alpha · 5d ago
Biogen: LAQEMBI's $10 Billion Potential
Biogen's latest alzheimer's drug, aduhelm, faced challenges after fda approval. The company's latest drug, a new type of alzheimer's treatment, has raised concerns. Biogen has a $10 billion potential, according to main street investor's analysis of the stock.
Seeking Alpha · 5d ago
Comparative Study: Biogen And Industry Competitors In Biotechnology Industry
Biogen and idec merged in 2003. Biogen has several drug candidates in phase 3 trials in neurology-related fields. The company competes in the biotechnology industry. The stock is undervalued compared to the industry average, and has potential to grow. The industry comparison includes biogen's key competitors.
Benzinga · 11/28 16:00
More
About BIIB
Biogen Inc. is a global biotechnology company. The Company is focused on discovering, developing and delivering therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis, spinal muscular atrophy (SMA) and Alzheimer's disease. It is focused on advancing its pipeline in neurology, neuropsychiatry, specialized immunology and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; FUMADERM for the treatment of severe plaque psoriasis, and SKYCLARYS (omaveloxolone). It is also advancing its mid-to-late stage programs, including zuranolone for major depressive disorder (MDD) and postpartum depression (PPD); BIIB080 for Alzheimer's disease; tofersen for amyotrophic lateral sclerosis (ALS), and both litifilimab and dapirolizumab pegol for certain forms of lupus.

Webull offers Biogen Inc stock information, including NASDAQ: BIIB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIIB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIIB stock methods without spending real money on the virtual paper trading platform.